Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy
Primary Purpose
Gastrointestinal Disease
Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cryobiopsy probe, administered to study participants
Sponsored by
About this trial
This is an interventional device feasibility trial for Gastrointestinal Disease focused on measuring Biopsy, EGD, Endoscopy, Cryobiopsy, OCT
Eligibility Criteria
Inclusion Criteria:
- Scheduled for an elective esophagogastroduodenoscopy with biopsy.
- 18 years of age or older.
- Able to provide informed consent.
Exclusion Criteria:
- According to standard of care.
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Cryobiopsy probe as a tool for biopsy
Arm Description
Cryobiopsy probe, administered to study participants.Testing the efficacy of a novel cryobiopsy probe in acquiring tissue samples.
Outcomes
Primary Outcome Measures
Evaluation of Cryobiopsy probe
Evaluation of Cryobiopsy probe in obtaining tissue samples over .5mm
Secondary Outcome Measures
Full Information
NCT ID
NCT03566160
First Posted
May 25, 2018
Last Updated
January 12, 2023
Sponsor
Massachusetts General Hospital
Collaborators
Bill and Melinda Gates Foundation
1. Study Identification
Unique Protocol Identification Number
NCT03566160
Brief Title
Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy
Official Title
Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
September 5, 2018 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
December 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
Bill and Melinda Gates Foundation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Environmental enteric dysfunction (EED) is a poorly understood condition characterized by intestinal inflammation and loss of barrier function that is prevalent in regions of the world with inadequate sanitation and hygiene. EED is a major driver of malnourishment, poor neurological development, stunting, oral vaccine failure, and infection, affecting 25% of all children globally and causing over a million deaths each year.
Progress towards understanding EED and developing effective interventions has been hampered by an inability to evaluate the intestinal mucosa of populations in impoverished regions of the world where this condition is endemic. In order to prevent the deleterious and permanent sequelae of the disease, there is a need for effective diagnosis and intervention to be implemented in EED patients before the age of 2. Currently, the only means for directly evaluating the intestine is endoscopy with mucosal biopsy. Unfortunately, endoscopy is untenable for the study of EED because of limited resources and the high cost. As a result, there is a clear, unmet need for a less invasive tool that can be used in low-and-middle-income-countries (LMICs) to evaluate the intestine in population with EED.
This work is supported by a grant from The Bill and Melinda Gates Foundation (BMGF). The overall goal is to provide a minimally invasive means of obtaining detailed infantile intestinal tissue information that is needed for the development of effective EED interventions. Obtaining biopsies will play a critical role in gathering the detailed intestinal tissue information.
The purpose of this study is to explore the feasibility of utilizing a cryobiopsy probe to obtain biopsies in adults.
Detailed Description
This study will test the capacity of a gastrointestinal tract cryobiopsy probe that Tearney Lab investigators have designed to obtain biopsies from the upper GI tract.
A total of twenty (20) subjects, adults 18 years of age and older, scheduled for elective esophagogastroduodenoscopy with biopsy will be enrolled in this study.
A maximum of 3 cryobiopsies per subject will be collected. After each cryobiopsy is complete, the endoscopist will then take 1 standard forceps biopsy from the area adjacent to where cryobiopsy was performed. A maximum of 3 standard forceps biopsies for research purposes only will be taken. Biopsy collection will be performed at the discretion of the endoscopist. The standard forceps biopsy sites will also be monitored directly throughout the entire experimental procedure. The total experimental procedure time will not exceed 15 minutes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Disease
Keywords
Biopsy, EGD, Endoscopy, Cryobiopsy, OCT
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Cryobiopsy probe as a tool for biopsy
Arm Type
Experimental
Arm Description
Cryobiopsy probe, administered to study participants.Testing the efficacy of a novel cryobiopsy probe in acquiring tissue samples.
Intervention Type
Device
Intervention Name(s)
Cryobiopsy probe, administered to study participants
Intervention Description
Cryobiopsy probe as a tool for gastrointestinal biopsy
Primary Outcome Measure Information:
Title
Evaluation of Cryobiopsy probe
Description
Evaluation of Cryobiopsy probe in obtaining tissue samples over .5mm
Time Frame
3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Scheduled for an elective esophagogastroduodenoscopy with biopsy.
18 years of age or older.
Able to provide informed consent.
Exclusion Criteria:
According to standard of care.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guillermo Tearney, M.D PhD.
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy
We'll reach out to this number within 24 hrs